Zimmer Biomet heads into its July 28 earnings report carrying one of the more interesting short-interest setups in MedTech — a third more short exposure than a month ago, yet with a stock that has quietly recovered.
Short interest has jumped 33% over the past month, reaching nearly 6% of the free float at around 11.9 million shares. That's a meaningful build, even as the stock has climbed 4.3% over the same period to close at $91.35. The divergence is the key tension here: bears have been adding exposure into price strength, a setup that creates a more asymmetric reaction to the print in either direction. Borrow conditions offer no signal that this is a crowded or desperate trade. Cost to borrow is just under 0.5%, down modestly on the week. Availability remains deep at roughly 564% — meaning nearly six shares are available to borrow for every one currently lent out. The lending market is relaxed. Meanwhile, options positioning has shifted noticeably less defensive than usual. The put/call ratio is at 0.82, running about 0.08 below its 20-day average of 0.90, suggesting options traders are leaning slightly more constructive into the release rather than hedging hard.
The bear case rests on execution risk that pre-dates this quarter. ZBH lost two large US knee accounts and is still working through the transition to a direct sales model — disruptions that have kept its growth rate below peers like , which gained 3.5% on the day and 3.2% on the week compared to ZBH's more muted 0.3% weekly gain. Analysts broadly reflect this caution. The mean price target is $98.60 against a current price of $91.35 — modest upside for a stock that has underperformed. BMO initiated coverage at Market Perform in early July with a $95 target, while Evercore maintained its Outperform but trimmed its target from $120 to $110 — both signals of tempered conviction. The bull case centres on ZBH's dominant position in the orthopedic reconstructive market and the argument that the Q1 beat on sales, margins and EPS showed the underlying business remains intact. Factor scores add an interesting layer: the analyst recommendation divergence ranks in the 95th percentile, meaning the spread of opinion across the Street is unusually wide — a reflection of genuine disagreement rather than consensus drift.
Institutionally, Dodge & Cox remains the largest disclosed holder at 12.2% of shares, and added 130,400 shares as of end-June, suggesting at least one long-oriented value manager sees the dislocation as an opportunity. Harris Associates and Capital Research have also been adding. The recent earnings history, however, offers a sobering reference: the April 28 print saw the stock fall 13.5% on the day and 10.3% over the following five sessions. The May prints were far more muted — a -1.1% and +0.4% initial move respectively — but the April episode is the benchmark bears are likely measuring against.
The print on July 28 will test whether the sharp short rebuild over the past month reflects well-founded concern about the knee account losses and channel disruption, or whether it becomes fuel for a squeeze if ZBH can again outperform on the numbers as it did in Q1.
See the live data behind this article on ORTEX.
Open ZBH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
